Study summary

Adding durvalumab to chemotherapy doubled 3-year survival

TOPAZ-1 3-year results · 685 people, phase 3, double-blind · Published May 2025, Journal of Hepatology

14.6%alive at 3 years with durvalumab, vs 6.9%

What was tested

Three-year follow-up of durvalumab, an immunotherapy, added to gemcitabine and cisplatin chemotherapy as first treatment for advanced bile duct and gallbladder cancer.

What they found

Median survival was 12.9 vs 11.3 months.
14.6% were alive at 3 years vs 6.9%.

What it means

Confirms immunotherapy plus chemotherapy as the first treatment for advanced disease.

J Hepatol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.